A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
Status:
COMPLETED
Trial end date:
2024-07-23
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants. The safety and tolerability of orforglipron and carbamazepine when given separately or together will also be evaluated. The study may last up to approximately 77 days for each participant.